Culture Under Fire

Sequoia Capital Reportedly Targets $10B for AI and Reindustrialization Strategy

Sequoia Capital is reportedly committing about $10B in new capital, the largest capital commitment in the firm's 54-year history. The number matters, but what Sequoia intends to finance says more about where venture capital is heading.

The strategy under co-stewards Alfred Lin and Pat Grady operates across two increasingly connected economies: advanced AI software and the physical infrastructure required to turn intelligence into something useful at industrial scale. Generative AI remains central, but Sequoia is also pushing deeper into defense, industrial robotics, semiconductor manufacturing, energy, and supply-chain reshoring.

The reported $10B commitment follows approximately $7B raised for Sequoia's expansion strategy in April 2026. That earlier vehicle increased the firm's late-stage capacity across the U.S. and Europe. The new commitment adds to that strategy rather than rewriting the April fundraise.

The economics explain the escalation. AI is making some software dramatically cheaper to build while making frontier models, compute infrastructure, robotics, manufacturing, and physical systems brutally expensive to scale. Sequoia already has exposure across that divide through OpenAI, Anthropic, Physical Intelligence, Cobot, Nominal, and Zipline.

That is where the reindustrialization thesis becomes interesting. Software intelligence increasingly has to survive contact with factories, machines, energy systems, supply chains, regulation, and physical infrastructure. The companies building that bridge cannot all be financed like lightweight SaaS businesses. Hardware, compute, facilities, manufacturing, testing, and deployment change the capital equation.

For founders, the lesson is not to raise more. It is to understand which layer of the stack you are building and what that layer demands. Capital-light software can move with extraordinary speed. Frontier models and physical systems carry different costs, timelines, and execution risks. Calling all of it AI does not make the economics identical.

For limited partners, approximately $10B represents a much larger wager that exceptional private companies will continue absorbing enormous amounts of capital before reaching public markets. For Sequoia, it is also a defining capital move under Alfred Lin and Pat Grady as they shape the firm's next era.

Don Valentine started Sequoia in 1972 with a $3M first fund. More than five decades later, its new leaders are reportedly contemplating capital commitments measured in tens of billions because technology itself has become heavier.

Sequoia's bet is no longer confined to what happens on a screen. Intelligence is moving into machines, factories, energy systems, defense, and infrastructure. The $10B gets the headline. Where that money goes will tell us considerably more.

G Squared VII Closes With $2.3B for Private Liquidity

G Squared just closed G Squared VII with $2.3B in commitments, its seventh and largest flagship, and the number matters for reasons that have very little to do with trophy size.

The fund lands in a private market that has spent years asking the same awkward question: what happens when great companies keep getting older, larger, and more valuable without going public? Capital can wait. Employees, early investors, and cap tables are not always built for endless patience.

Larry Aschebrook founded G Squared in 2011 around that tension. The firm invests through select primaries, direct secondaries, bespoke structured investments, and company-led tenders when a business needs liquidity without forcing a conventional exit. The strategy reflects how venture-backed companies actually behave now.

G Squared's current and former portfolio spans Anthropic, Brex, Coursera, Databricks, Instacart, Lambda, Lyft, Spotify, Toast, and Wiz. The names show access. The harder advantage is pairing that access with the ability to solve liquidity problems across a company's lifecycle.

The timing makes G Squared VII especially interesting. Global secondary-market transaction volume reached $240B in 2025, up 48% year over year and the largest annual total on record. That is not a niche warming up. It is a market absorbing the consequences of longer holding periods, uneven IPO windows, and shareholders who still need a path to cash.

G Squared reported deploying more than $620M in 2025. Now it has a new $2.3B flagship behind a strategy built for the gap between private-company growth and public-market timing. The fund does not make the liquidity problem disappear. It gives the firm more room to price it, structure it, and act when a high-quality company or shareholder needs an answer.

For founders, the lesson is not to treat secondaries as distress. A thoughtful tender can clean up a cap table, reward early risk, and preserve operating focus without forcing an IPO on somebody else's calendar.

For investors, the signal is equally plain. The private secondary market is becoming infrastructure, not an afterthought. As it grows, scale alone will not be enough. Managers still need relationships, underwriting discipline, and the nerve to say no when access arrives wearing a premium price tag.

Larry Aschebrook and the G Squared team now have $2.3B behind a thesis the firm has been building around since 2011. Raising the fund is the headline. Building around a structural problem before the rest of the market had to admit it was structural is the more durable story. The market finally caught up with the original thesis.

River AI Raises $1.1B to Build User-Owned Personal AI

River AI just raised $1.1B across its Seed and Series A, led by General Catalyst and AMP PBC, with strategic investment from NVIDIA and AMD Ventures and participation from Y Combinator and Temasek. That is a company entering the AI market with serious new capital to build both the infrastructure and the products running on it.

Co-founder and CEO Igor Babuschkin is betting the next AI battle will not be won by giving everyone the same giant model and a longer prompt box. River AI wants organizations to train, tune, and own intelligence built around how they work. The difference sounds philosophical until the infrastructure bill shows up.

River API is the first commercial wedge. It offers LoRA fine-tuning and reinforcement learning for open-weight models from 35B to 1T parameters. River AI says enterprises can complete a complex RL run in 15 to 20 minutes and save 2x to 4x versus closed-source alternatives. Those are company-reported claims, but the argument is sharp: stop renting generic behavior when you can shape the weights.

Enterprise AI has spent years selling access while quietly keeping ownership, adaptation, and economics somewhere else. The model provider owns the infrastructure. The customer keeps paying for access. River AI is trying to shift more technical and commercial control into the customer's hands.

General Catalyst and AMP PBC provide institutional backing. NVIDIA and AMD Ventures connect the round to compute, while Y Combinator and Temasek broaden the syndicate. That is serious backing for model specialization and user control, not proof River AI has solved personal AI.

Igor Babuschkin brings experience from Google DeepMind, OpenAI, and xAI, where large-scale deep learning and reinforcement learning were not presentation slides. River AI says its founding team also includes veterans of xAI and Tesla. The API is only the opening move.

The longer plan reaches across training infrastructure, continually learning models, interfaces, and personal hardware. $1.1B buys room to attempt that stack. It does not buy certainty or the engineering required to make personal AI trustworthy.

The foundation-model race has concentrated power in a few labs, while enterprises want more control over data, costs, and model behavior. River AI is entering through the gap between using AI and owning what the AI learns.

River AI and Igor Babuschkin have raised the kind of round that removes "not enough resources" from the excuse list. Now the market gets to watch whether that capital can become durable customer-owned intelligence.

Global AI Closes $441M Debt Facility for Sovereign AI

Global AI just put $441M of senior secured debt behind a specific bet: the next phase of AI infrastructure will be won by whoever can give enterprises and nations control, not merely compute.

The company announced its first debt raise on August 10, with J.P. Morgan leading and arranging the facility alongside unnamed lenders. Venture money can fund a vision. Senior secured debt shows up when that vision needs land, power, cooling, servers, construction schedules, and contracts sturdy enough to make a credit committee stop frowning for five minutes.

Global AI is building dedicated, single-tenant, air-gapped environments for AI training and inference. This is not another shared cloud with a sovereignty sticker on the invoice. It is infrastructure designed so customers can keep sensitive data, models, and operations inside controlled environments while running at hyperscale.

Global AI says demand is showing up in a form lenders understand. CEO Sami Issa said the company has $6.2B in contracted revenue, including $1B already built and delivered. Those are company-reported figures, but they help explain why a two-year-old infrastructure company can ask the debt market for more than a polite introductory meeting.

The capital is intended to accelerate Global AI's U.S. expansion as it works toward 1 GW of critical capacity by the end of 2029. The company has been building around NVIDIA systems and a partnership with HUMAIN, creating a stack that stretches from land and power through liquid cooling and GPU-dense compute. That is less software startup, more industrial platform operating on a software-era clock.

Chairman and CTO Dr. John E. Kelly III and CEO Sami Issa are operating where technical ambition collides with electrical reality. The business has to secure megawatts, cool expensive hardware, satisfy customers, and pay the lender back. The spreadsheet does not care how visionary the keynote sounded.

Financing terms beyond the facility's size and senior secured structure were not disclosed. Neither were the other lenders. That leaves an important signal, not a complete underwriting picture: major credit is moving toward sovereign AI capacity, but execution will decide whether it becomes durable infrastructure or interest expense with better branding.

The Global AI team now has $441M of financial capacity behind that expansion. The question is whether dedicated, controlled compute becomes a durable infrastructure category, and whether Global AI can turn the financing into enough operational proof that the next raise feels less like a bet and more like a pattern.

Flagler Health Raises $50M for AI-Native MSK Platform

Flagler Health just raised a $50M Series B to build the AI operating system for musculoskeletal care. The real fight is with the invisible tax inside every clinic: stalled referrals, stacked calls, slow authorizations, and clinicians doing administrative work instead of clinical work.

Bessemer Venture Partners led the round, with SignalFire, Alumni Ventures, Streamlined, 186 Ventures, Proof VC, Tribeca Venture Partners, and Offscript participating. The financing brings Flagler Health's total capital raised to $63M and gives the company a larger runway to prove connected operations can beat another pile of disconnected tools.

Flagler is not selling an AI note-taker with a shiny coat of paint. Its platform works inside existing electronic medical record systems and coordinates triage, referrals, scheduling, engagement, care management, prior authorization, billing, analytics, and communications across the patient lifecycle. MSK clinics suffer from chains of small failures, not one broken task.

The company says it has expanded to thousands of providers across more than 36 states in less than three years. It reports an average of $164,000 in additional annual revenue per provider and says 87% of participating patients improve in at least one area, including pain, mobility, sleep, or mood. Those are company-reported numbers, and scale will test them harder than any pitch deck could.

The founding team is built for that test. CEO Albert Katz lived the operational problem inside an MSK clinic. CMO Dr. Leon Anijar brings clinical authority, while CTO Will Hu turns that knowledge into infrastructure that works behind the scenes instead of demanding another login.

Flagler says MSK conditions affect more than half of U.S. adults and account for more than $400B in annual healthcare spending. Every handoff among providers, payers, staff, and patients creates another place for money, time, or care continuity to disappear.

Albert Katz, Dr. Leon Anijar, Will Hu, and the Flagler Health team now have $50M in new capital behind the next test: proving one operating layer can help thousands of clinics move patients and money through the same system without turning clinicians into software administrators.

If Flagler can scale that model while preserving outcomes and trust, the most important product in healthcare AI may not be the assistant beside the clinician. It may be the infrastructure quietly keeping the entire clinic from leaking value between visits.

Epicrispr Raises $90M Series C to Advance EPI-321 Trial

Epicrispr Biotechnologies just closed a $90M oversubscribed Series C, and the timing says more than the number. The round was co-led by Octagon Capital and Janus Henderson Investors, with Fidelity Management & Research Company, Cormorant Asset Management, Duquesne Family Office, Sanofi Ventures, funds managed by abrdn Inc., Angelini Ventures, Readout Capital, and existing investors joining the syndicate. Anran Li, Ph.D., of Octagon Capital is also joining the board.

That is a serious cap table gathering around a serious clinical question: can epigenetic medicine change disease biology without permanently changing the underlying DNA sequence?

Epicrispr is trying to answer it with EPI-321, a one-time AAV-delivered therapy for facioscapulohumeral muscular dystrophy, or FSHD. The program is designed to suppress DUX4, the genetic driver of the disease, using the company's Gene Expression Modulation System, or GEMS.

Traditional gene editing is often framed around changing genetic code. Epicrispr's approach is built around regulating which genes are expressed and how strongly. Less molecular demolition, more precise control of the switches.

The financing follows early company-reported Phase 1/2 data. As of a May 12 cutoff, nine patients had been treated, with no serious adverse events reported at that time. The first three evaluable patients showed increased lean muscle volume at six months, averaging about 370 mL. The study is small, open-label, and early, so nobody should confuse signal with proof. But investors rarely assemble a syndicate like this because the slide deck had good fonts.

Epicrispr later said all 12 participants had been enrolled and dosed. The new capital will push EPI-321 toward pivotal studies while expanding the broader pipeline, GEMS platform, and manufacturing capabilities.

This is also not Epicrispr's first trip through the financing gauntlet. The company announced a $55M Series A in 2022 and a $68M first close of its Series B in 2025. Add the latest round, and Epicrispr has disclosed at least $213M across those financings.

Scientific founder Lei Stanley Qi, Ph.D., helped build the intellectual foundation. CEO Amber Salzman, Ph.D., and the Epicrispr team now have to turn that foundation into clinical execution, manufacturing discipline, and a program regulators can evaluate at pivotal scale.

Epicrispr Biotechnologies, Amber Salzman, the team, and its investors now have $90M behind the next stage. The money is real. The early signal is interesting. The hard part is converting that signal into evidence strong enough to carry EPI-321 through pivotal development.

Fisent Raises $4.3M for Regulated Enterprise AI

Fisent Technologies just closed a $4.3M first priced venture round, and the interesting part is not that another AI company found capital. It is where the money is being pointed: deployment, enablement, and the stubborn last mile between a clever model and a regulated enterprise trusting it with real work.

FINTOP led the round, with continued participation from Pegasystems, bringing Fisent's total funding to $6.3M. FINTOP Partner John Philpott is also joining the board. That combination gives the deal more than a balance-sheet story. FINTOP brings a network built around roughly 100 banks and financial-services companies, while Pega extends a relationship already rooted in enterprise workflow automation.

Fisent's pitch is direct. Its BizAI software takes unstructured content inside complex workflows and turns it into automated outcomes. Contracts, onboarding files, customer requests, purchase orders, and other knowledge-heavy processes stop waiting for a human to read every page before the system can move. BizAI Studio pushes that idea further by letting non-technical teams build, deploy, and refine workflows without putting every change into an IT queue.

Enterprise AI has reached an awkward age. Building a demo keeps getting easier. Getting software through security, governance, integration, testing, and production accountability still makes grown companies stare at calendars like the meeting might cancel itself.

Fisent says the proof is showing up in the operating numbers. The company reported 206% year-over-year revenue growth in 2025, 173% net revenue retention, and zero customer churn for a third consecutive year. It also secured its first Fortune 50 customer in 2026. Those are company-reported metrics, but they explain the investor logic: expansion inside demanding accounts is a stronger signal than a pile of pilots posing for a roadmap.

Founder and CEO Adrian Murray is using the new capital to expand enterprise go-to-market, customer enablement, deployment engineering, and product development. CTO Jeff Irving and COO Brent Baiotto are building around the same constraint every serious enterprise AI vendor eventually meets: the product is only as valuable as the workflow it can reliably enter, govern, and improve.

Adrian Murray, Jeff Irving, Brent Baiotto, the Fisent team, FINTOP, John Philpott, and Pegasystems now have the next stage in front of them. The challenge is no longer proving that generative AI can understand content. It is proving how much important work can move once enterprises trust the system carrying it.

GEM Closes $82M Seed & Micro Venture Fund

GEM just closed an $82M fund for a corner of venture capital that institutions often want but struggle to reach without getting lost in a maze of small vehicles, short track records, and access constraints.

The Charlotte-headquartered investment manager announced the final close of GEM Seed & Micro Venture Fund, LP, on August 11. The total cleared its $60M fundraising target and stepped over an $80M internal hard cap. That is not a rounding error. It is a clean signal that LPs still want early-stage venture when the route into it feels disciplined.

Commitments came from healthcare institutions, university endowments, family offices, and GEM's OCIO clients. Nobody showed up because "micro" looks cute on an allocation memo. They showed up because the earliest end of venture is increasingly fragmented while familiar multi-stage brands keep getting larger.

GEM is aiming directly at that split. The fund will make primary commitments to micro, pre-seed, and seed-stage vehicles, generally those below $200M. It gives institutions a way to build exposure to emerging venture firms and the companies they back without pretending that picking outliers is a casual side project.

Kate Simpson, Managing Director in GEM's Investment Research Group, oversees the venture platform. Her argument is direct: early-stage venture can matter inside a broader portfolio, but manager selection must separate genuine access from expensive tourism. GEM has invested in venture since 2007, so the thesis feels earned rather than borrowed.

Jay Ripley, GEM's Head of Investments and Deputy Managing Partner, framed the fund as a continuation of the firm's work with promising investment talent across private markets. The value proposition is not simply "more seed." It is finding managers before access becomes a velvet rope and their firms grow into the same scaled platforms every institution already knows.

For operators, the lesson sits below the fund close. Capital still moves toward specialists who can explain their edge, how they underwrite it, and why the process survives noisy markets. Emerging managers build institutional credibility through repeatable diligence and portfolio discipline, not volume. For LPs, access without selection is just a longer list of names.

An $82M close will not settle the debate over venture allocation. It does show where Kate Simpson, Jay Ripley, and the GEM team see useful territory: smaller funds, earlier company formation, and managers whose best work may happen before the market learns their names.

Heaviside Raises $60M Series B, Partners With Nammo

Heaviside Industries raised a $60M Series B at a $600M valuation, three months after emerging from stealth. That speed gets attention. The stronger signal is what arrived beside the money: a strategic partnership with Nammo to supply warheads for Heaviside's multi-domain precision munitions.

Capital without production is a very expensive press release. Heaviside is trying to build the part that matters after the headline: a repeatable system for putting precise, autonomous capability into the field across air, land, and sea, even when GPS and the electromagnetic environment refuse to cooperate.

Felicis led the round. Hedosophia participated significantly, with Menlo Ventures, Cantos, Flume Ventures, Qstar Capital, Friends & Family Capital, Anorak Ventures, MVP Ventures, and others joining. Heaviside announced its $28M Series A in May.

That takes Heaviside's disclosed funding across those two rounds to at least $88M. It also puts a young company on a short clock. A $600M valuation can buy room to move, but it turns manufacturing, hiring, customer commitments, and delivery into the scoreboard.

Founder and CEO Phillip Walker has built the company around autonomous precision strike technology for U.S. and allied special operations and conventional forces. Heaviside's portfolio spans MOTH for electromagnetic signal intelligence and land-spectrum awareness, TYR as an autonomous aerial munition, and HYDRA as an autonomous underwater munition.

Nammo changes the shape of that bet. The Norway-headquartered company operates 27 production sites across 12 countries and brings an established munitions supply chain. Under the partnership, Nammo will supply warheads for Heaviside's platforms, giving the startup a more credible path from autonomous guidance and platform design to integrated systems.

Heaviside says the Series B will expand production, hiring, customer fulfillment, and U.S. infrastructure. Those are practical uses of capital. They are also where the thesis gets tested, because defense hardware is ultimately judged by what ships, works, and can be replenished.

Phillip Walker and the Heaviside team have moved from a May stealth exit to an August growth round, while Felicis, Hedosophia, Menlo Ventures, and the broader syndicate are financing a production challenge as much as a technology company.

For operators, the strongest defense funding story is rarely just the amount raised. It is evidence that product, supply chain, manufacturing, and demand are beginning to lock together. Heaviside now has more capital and a serious industrial partner. The next proof is delivery.

Form Energy Raises $750M Series G to Scale 100-Hour Batteries

Form Energy just raised $750M in Series G financing, and the story is that a battery built around iron, air, and water has moved from an ambitious laboratory thesis into a serious piece of grid infrastructure.

T. Rowe Price led the round after leading Form Energy's Series F. Sequoia Capital, Janus Henderson, Franklin Templeton, and PEAK6 Investments joined as new investors, with Breakthrough Energy Ventures, TPG Rise Climate, Coatue, GE Vernova, and others returning.

The investor list matters, but the timing matters more. Form Energy says its backlog grew from roughly 20 GWh to 80 GWh earlier this year, powered by agreements with Xcel Energy and Google, Crusoe, and FuturEnergy Ireland. Capital is showing up after the company built manufacturing capacity, tested the system at scale, and signed customers with very large electricity problems.

Form Energy's first commercial product is a grid-scale iron-air battery designed to store energy for 100 hours. Lithium-ion batteries are excellent at moving electricity across hours. Form Energy is aiming at the multi-day gaps that appear when weather, demand, and grid reliability stop cooperating with the spreadsheet.

The money will accelerate manufacturing at Form Factory 1 in Weirton, West Virginia, and support commercial deployments. The factory sits on the former Weirton Steel site, giving the story a clean symmetry: an old center of American industry is producing a new class of infrastructure, with iron still doing the heavy lifting.

Mateo Jaramillo, Ted Wiley, William Woodford, Yet-Ming Chiang, and Marco Ferrara founded Form Energy in 2017. The company now employs nearly 1,000 people, has raised more than $2B in equity, and is preparing projects measured in tens of gigawatt-hours.

The leadership bench is changing with the scale. Navneet Govil has joined as CFO after senior finance leadership at SoftBank Investment Advisers, while Wes Sloan has joined as COO after running large-scale battery production at Panasonic Energy North America. Those are not decorative hires. They are the jobs you fill when manufacturing discipline and capital formation become as important as the original chemistry.

Form Energy, Mateo Jaramillo, Ted Wiley, William Woodford, Yet-Ming Chiang, Marco Ferrara, and the investors backing this next phase now have a much larger commercial test ahead. The question is whether multi-day storage can become a standard utility asset fast enough to meet rising data-center demand and a grid that increasingly needs clean power to behave like firm power. Form Energy now has $750M more to make its answer difficult to ignore.

MarginEdge Raises $80M Series D and Debt Funding

MarginEdge just raised $80M in Series D equity and debt funding, which is a lot of capital for a company built around problems most people notice only after the restaurant closes and somebody is still reconciling invoices.

Ten Coves Capital and Schooner Capital led the equity portion, with Derive Ventures and Osage Venture Partners participating. The equity and debt split was not disclosed, and neither was the lender. What is clear is that investors still back vertical software when it owns a painful workflow and keeps finding adjacent ones worth solving.

MarginEdge started with restaurant operators doing the work restaurant operators hate. CEO and co-founder Bo Davis brought years of operating experience. Co-founder Roy Phillips helped build and expand restaurant concepts. CTO and co-founder Brian Mills helped turn that frustration into software connecting invoices, purchasing, inventory, food costs, menu performance, bill pay, and accounting data.

Restaurants rarely lose margin in one cinematic disaster. They lose it quietly. A vendor price moves. A recipe cost drifts. Inventory does not match usage. A manager gets the right report three weeks after the useful decision disappeared. MarginEdge moves that information closer to the moment when an operator can still act.

The company says it serves 11,000 clients across the U.S. and Canada, and the product line is widening. MarginEdge's 2026 releases include SmartPrep, the restaurant-focused [me] Card, QR-supported inventory, a data-aware assistant, and an early-access product that lets eligible customers spread vendor invoices across weekly payments.

The stronger signal inside this round is the operating layer taking shape. MarginEdge is connecting purchasing data, payments, inventory, recipes, sales, and cash flow so each can inform the others. The software becomes harder to replace as it moves closer to the financial pulse of the business.

Vertical SaaS gets mocked whenever the market decides every category needs an AI wrapper and a new acronym. MarginEdge offers the older, tougher lesson: know the operator, own the workflow, and earn the right to expand. In restaurants, useful software does not need theater. It needs to surface a problem before dinner service turns it into tomorrow's regret.

Bo Davis, Roy Phillips, Brian Mills, and the MarginEdge team now have $80M in equity and debt funding behind that expansion. The next question is whether MarginEdge can become the financial operating system for restaurants or whether the stack remains too fragmented for one platform to own the whole table.

Diald Raises $1M for Conversational CRE Underwriting

Diald just added $1M in follow-on funding led by Feedback Ventures, bringing its disclosed total to $4.75M. The dollar figure is modest by venture theater standards. The signal is sharper: the investor that led Diald’s $3.75M seed round came back as the company rebuilt its commercial real estate underwriting platform for a wider market.

Commercial real estate has never suffered from a lack of information. It suffers from information arriving in different formats, from different vendors, on different clocks, while someone still has to decide whether the exit cap rate makes sense. Institutional firms buy systems and hire analysts. Family offices, owner-operators, and independent investors are often left with spreadsheets, browser tabs, and professional instinct.

Founder and CEO Steven Song is attacking that gap with conversational underwriting. Give Diald an address or offering memo, explain the deal in plain language, and the platform assembles research, comparable-property analysis, a financial model, and exit assumptions while showing its work. No ritual sacrifice to the spreadsheet gods required.

The rebuilt product adds two distinct reads. Its Neighborhood Investment Rating examines safety, infrastructure, regulation, and neighborhood dynamics. Its Confidence Score tests how much support exists for an exit-cap-rate assumption using qualitative context and market evidence. The score does not make the decision. It makes the assumption easier to interrogate.

Diald says 19 specialized AI agents scan more than 1.7M media and institutional sources, with licensed data from Moody’s Analytics, Green Street, and LightBox. The company also reports more than $210B in real estate volume analyzed, 300+ accounts, customers in 10+ countries, and nine patent applications across five jurisdictions. Those are company-reported numbers, but they help explain why Feedback Ventures chose to double down.

The timing matters as much as the capital. Diald is moving from an enterprise-shaped product toward packages priced from $0 to $200 per month, opening institutional-style analysis to buyers who were never going to build an institutional research department. This is not merely a cheaper dashboard. It is an attempt to change who gets to pressure-test a deal before real money moves.

Steven Song, COO Samantha Um, the Diald team, and Feedback Ventures now have the broader market to test. The follow-on is not the whole story. The real question is whether wider access produces better underwriting discipline for owners the legacy software stack barely noticed, and whether Diald becomes the system they keep open when the deal gets uncomfortable.

ClearJet Raises $25M Series B for Airline Parcel Network

ClearJet just raised a $25M Series B led by Edison Partners, bringing reported funding to roughly $40M. Venture53, Origin Ventures, SaltVC, and SpringTime Ventures returned for the round.

ClearJet does not own a fleet of planes. It connects shippers to unused cargo space on commercial flights already moving between U.S. cities, then coordinates airport sorting and the final-mile handoff through one operating layer. Founder and CEO Chris Guggenheim calls it a SuperCarrier. The simpler translation: make the country's existing logistics capacity behave like one configurable network.

Parcel delivery has spent decades asking retailers to choose among speed, cost, and control, then charging generously for the privilege of picking two. ClearJet's premise is different. If airlines, sort centers, and delivery providers already have the assets, the missing value sits in making those assets work together.

The company says its network spans 95 U.S. airports. ClearJet reports that it is profitable, revenue has more than tripled year over year, and top-line revenue is approaching nine figures. The company also reports more than 30M shipments delivered and says the model can cut shipping costs by as much as 35% while speeding delivery by 1–3 days. Those are company-reported figures, but they explain the investor interest.

Edison Partners is backing a logistics layer built around airline capacity, airport handling, sortation, parcel routing, and final-mile injection. The software matters. So does the operational scar tissue required to keep packages moving when weather, capacity, or carrier economics create an emergency meeting.

ClearJet's routing models choose parcel paths by cost, speed, and geography. The company is also building AI agents for rating, booking, tracking, and exception management. That is a better AI story than putting a chatbot near a warehouse and waiting for applause. The system can reroute because it is not married to one airline or final-mile provider.

CEO Chris Guggenheim and CTO Jay Winters are building that network with backing from Edison Partners, including Ryan Ziegler, and returning investors Venture53, Origin Ventures, SaltVC, and SpringTime Ventures. The leverage comes from coordinating assets instead of owning all of them.

The next chapter includes returns, international shipping, more airport coverage, and better visibility. If ClearJet executes, the larger shift will not be air versus ground. It will be fixed carrier networks versus programmable delivery infrastructure, with ClearJet betting the more flexible network wins.

Amplifica Raises $26M to Advance Hair-Growth Pipeline

Amplifica just closed an oversubscribed $26M Series B, and the bigger story is not another biotech round dressed up for a victory lap. It is a bet that dormant hair follicles may need a better signal, not another daily reminder that current options have limits. Tasso Partners, LLC led the financing, with participation from Eli Lilly and Company, principals of Scopia Capital Management, LP, and other new and existing investors.

Amplifica is developing injectable therapies for androgenetic alopecia. Its candidates are designed to regulate the hair-follicle growth cycle and reactivate follicles that remain present but dormant. Existing daily-use treatments such as finasteride and minoxidil can help some patients. Amplifica is testing a different proposition: stimulate new growth through signaling molecules and complementary mechanisms.

The pipeline includes AMP-303, AMP-203/AMP-506, and AMP-601. Amplifica says it has four differentiated programs, while early first-in-human work on AMP-303 produced a measurable hair-growth signal after one treatment cycle. That is encouraging clinical evidence, not a finish line.

The new capital will support continued clinical development across the injectable pipeline, giving Amplifica more shots on goal across distinct mechanisms instead of forcing one molecule to carry the whole future on its back.

Frank Fazio serves as President and CEO. Wajdie Ahmad is Executive Chairman, Maksim Plikus, PhD, is CSO, William Rassman, MD, is CMO, and Spencer F. Segura is Director. Plikus brings the UC Irvine regenerative-biology research behind the company into the clinic.

Amplifica previously announced an $11.8M Series A in 2022. Together, its two announced priced rounds total at least $37.8M. The sequence matters more than the tally: finance the science, establish an early human signal, then fund the clinical work needed to learn whether that signal can become a durable treatment.

More than 50M men and 30M women in the United States are estimated to face androgenetic alopecia. A better therapeutic option would not be a vanity footnote. It would be a meaningful clinical product in a market Amplifica estimates above $6B.

Frank Fazio, Wajdie Ahmad, Maksim Plikus, William Rassman, Spencer F. Segura, and the Amplifica team now have the capital, pipeline, and strategic attention behind the next stage. What financing cannot provide is the part that matters most: clinical data strong enough to turn investor conviction into patient confidence.

Remepy Raises $36M to Take Hybridopa Into Phase III

Remepy just raised a $36M Series A to push medicine past the part where a prescription ends at the pharmacy counter.

O.G. Venture Partners and M Ventures, the strategic venture arm of Merck KGaA, led the round. NFX, Vine Ventures, Qumra Capital, TechAviv, 97212 Ventures, Fresh Fund, PsyMed Ventures, Tadmor Group, Key1 Capital, and IT-Farm Corp. also participated. The financing brings Remepy's total capital raised to $62M, with no valuation disclosed.

The money has a specific assignment. Remepy plans to expand pharmaceutical co-development partnerships, grow its Hybrid Drug pipeline and platform, and fund global Phase III development of Hybridopa, its investigational Parkinson's program. That pivotal work is expected to begin in Q4 2026.

Hybridopa pairs immediate-release levodopa/carbidopa with DopApp, an adaptive mobile protocol. It combines medication with physical, cognitive, behavioral, and speech interventions in one clinical program. A pill handles chemistry. Software works on care chemistry cannot carry alone.

That is the wager behind Remepy's Hybrid Drug category. Software is usually an accessory to medicine. Remepy is trying to make it part of the therapy itself, with clinical evidence, regulatory obligations, and intellectual property.

There is early evidence, with all the caution that "early" deserves. A peer-reviewed, 41-patient Phase IIa pilot reported a 9.7-point mean improvement on combined MDS-UPDRS Parts I, II, and III for Hybridopa versus 1.95 points for control. The study was partly company-funded. Hybridopa remains investigational and is not FDA approved.

Phase III is where the thesis must survive bigger numbers, broader populations, operational friction, and pivotal evidence. The Series A funds entry into the expensive part of that test.

The investor mix sharpens the story. M Ventures backs Remepy while its parent company collaborates with the company on Hybrid Drugs for rare tumors. O.G. Venture Partners brings growth capital, while NFX and other earlier investors return. Capital, clinical development, and pharmaceutical distribution are sitting at the same table.

Co-CEOs Dr. Michal Tsur and Or Shoval lead Remepy, alongside CTO Eran Etam and Chief Scientific Officer Prof. Amir Amedi. Their job is to prove the combination can behave like one regulated product, not two businesses wearing the same lab coat.

If Hybridopa's Phase III program validates the model at scale, this round could mark a more consequential shift: digital health moving from sitting beside pharma toward earning a place inside the prescription.